acute liver dysfunction associated with interferon-beta-1a (avonex®) use in a young female patient with relapsing-remitting multiple sclerosis (rrms)

background: it has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (rrms) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. we report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (avonex®) intramuscular injections in a young female patient with relapsing-remitting multiple sclerosis. case: the patient was 19 year-old female with clinically proved rrms, treated with interferon-beta-1a (avonex®) 30 µg weekly by intramuscular injections for two years. she was referred with clinical symptoms of liver dysfunction including abdominal peri-umbilical and right upper quadrant pain, anorexia and malaise, that constipation, dark urine and icterus. laboratory studies corroborated acute hepatitis state without any viral, autoimmune or drug-related causes. patient's status improved after two weeks of conservative therapy and withholding interferon. billirubin, liver function tests and liver enzyme values returned to normal. conclusion: interferon-beta compounds could have serious hepatic complications, and patients using interferon-beta-1a should regularly monitor their liver function.